Unlocking Precision, Empowering Immunity: AiCella, Where AI Fuels Cellular Innovation

WELCOME TO

AICELLA INC

DE-RISKING CELL THERAPY R&D

At Aicella, we’re at the forefront of revolutionizing CAR-T therapy development. The soaring demand for personalized cancer treatments has propelled us to create innovative tools that streamline processes, reduce bottlenecks, and significantly enhance patient outcomes. Our Insights^TM data dashboard stands as a beacon of efficient process design and analysis, catering to the evolving needs of the global CAR-T therapy market.

IP filing support based on AI Insights

cGMP-oriented Process Development

SOPs with recommended best practices

Tech transfer assistance to CDMOs

AICELLA INC

Our Vision

The Insights^TM tool serves as the cornerstone of a comprehensive offering tailored for academic and industry customers. This integrated partnership includes an interactive AI/ML Data Dashboard – Aicella Insights^TM – providing a succinct summary of critical process parameters correlated with patient responses.

Alongside this powerful tool:

Process development is done with Good Manufacturing Practices (GMP) in mind, which are the strict procedures that cell therapy manufacturers must comply with in order to provide therapies to patients. Keeping GMP at the forefront of our development efforts helps smooth that transition from the bench to the bedside.
While we trust and value our AI, the verification of AI generated process models in our own lab provides a critical bridge between models and the real world.
Standard operating procedures (SOPs) with recommended best practices. SOPs are the essential blueprints that companies need to move from a small scale manufacturing process to the clinic.
Assistance in transferring the AI generated procedures from the R&D team to the folks ultimately responsible for making the product, saving time and money.
We support our partners in filing their Investigational New Drug applications, which is the first step in moving a therapy from R&D to the clinic.
Intellectual filing support based on on Insights^TM driven elucidation of process development. The AI models are supplied as computer files that can be used.

Targeted Solutions

Leveraging Machine and Deep Learning based on real world models for process development – the data is the key. Our tools and services are meticulously crafted to cater to the distinct needs of pharmaceutical companies, biotech firms, research institutions, and academic centers engaged in CAR-T therapy development.

Our Commitment

We are committed to empowering our clients with cutting-edge solutions that optimize processes, augment decision-making, and drive meaningful advancements in CAR-T therapy development. By leveraging advanced technology and insightful analysis, we aim to revolutionize the landscape of personalized medicine.

OUR senior TEAM

Geoffrey Stephens

PhD, CEO, AiCella, Inc

Cliona Rooney

PhD, Professor, BCM-CAGT

Ron Rocca

CEO, Mindera

Mike Howell

PhD, CSO, Zura Bio

I was part of fledgling biotech enterprise, but was new to the field. AiCella sent me in the perfect direction and aided with the associated regulatory filings.

I am genuinely impressed with AiCella's groundbreaking work in AI-based cell therapy process development. As an assay development scientist, I understand the crucial role that precision and efficiency play in the development of cell-based therapies, and AiCella's innovative approach has left a lasting impression on me.

One of the most remarkable aspects of collaborating with AiCella is their profound understanding of the regulatory landscape and their commitment to compliance. As a company deeply engaged in the development of novel therapeutics, obtaining FDA approval is a complex and often arduous process.

FOR ANY Query

WELCOME TO

AICELLA INC

DE-RISKING CELL THERAPY R&D

IP filing support based on AI Insights

cGMP-oriented Process Development